Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
4 studies found for:    ERYTHERMALGIA, PRIMARY
Show Display Options
Rank Status Study
1 Completed
Has Results
Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia
Conditions: Primary Erythromelalgia;   Inherited Erythromelalgia
Interventions: Drug: XPF-002;   Drug: Placebo
2 Completed Study of XPF-001 in the Treatment of Pain From Primary/Inherited Erythromelalgia (IEM)
Conditions: Primary Erythromelalgia;   Inherited Erythromelalgia
Interventions: Drug: XPF-001;   Drug: Placebo
3 Enrolling by invitation A Phase 2a Study of BIIB074 in the Treatment of Erythromelalgia
Condition: Primary Inherited Erythromelalgia
Interventions: Drug: BIIB074;   Drug: Placebo
4 Completed Evaluation Of The Efficacy And Safety Of Single Doses Of PF-05089771 In Patients With Primary (Inherited) Erythromelalgia
Condition: Inherited Erythromelalgia
Interventions: Drug: PF-05089771;   Drug: Placebo

Indicates status has not been verified in more than two years